BioSpace News Archive

Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces publication a head-of-print in the Annals of Surgery of the “NEXUS Arch Multicenter Study Evaluating the Initial Experience with a Novel Aortic Arch Stent Graft System” by Planer et al.

Revelation Biosciences Inc. (Revelation), announced today that it has engaged MedWorld Advisors to optimize the value of Revelation’s diagnostic tool, REVID™.

Alphatec Holdings, Inc. (Nasdaq: ATEC), a provider of innovative spine surgery solutions dedicated to revolutionizing the approach to spine surgery, announced today that Pat Miles, Chairman and Chief Executive Officer, and Todd Koning, Chief Financial Officer, will participate virtually in the following investor conferences:

ABK Biomedical, Inc. announced the approval and initiation of a First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device, in collaboration with Auckland Hospital Research Unit, New Zealand.

Rheos Medicines today announced new preclinical data showing the potential for MALT1 inhibitors for the treatment of autoimmune and inflammatory diseases

Manhattan Scientifics Inc., initially funded and is the current owner of more that 50 million shares of Imagion Biosystems Ltd..

Incyte announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer’s 36th Annual Meeting, held from November 10-14, 2021 in Washington, D.C and virtually.

Apollo Endosurgery, Inc. announced the publication of a multi-center study of the X-Tack System in closing challenging gastrointestinal defects.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that clinical data on its therapeutic candidates Nyxol® and APX3330 will be featured in poster sessions as presentations at the upcoming American Academy of Ophthalmology (AAO) 2021 annual meeting to take place in New Orleans, November 12 – 15.

Venatorx Pharmaceuticals announced today that it has entered into a Research Collaboration and License Agreement with Roche to discover, characterize and develop new small molecule inhibitors of the Penicillin Binding Proteins (“PBPs”)